Market Research Reports Global Sarcopenia Treatment Market Size study, by | Page 2

Canada Sarcopenia Foundation, which is committed to forestalling and turning around the course of
metabolic disease and sarcopenia.
Expanding prevalence of sarcopenia over the grown-ups at an early age and the rising mindfulness
dimensions of the buyers is foreseen to drive the development in the pre-sarcopenia market over
the conjecture time frame. Based on sort, the Global Sarcopenia market is divided into Pre-
Sarcopenia, Sarcopenia, and Severe Sarcopenia. As of now, the market is commanded by sarcopenia
market with a larger part revenue share of 43.55% in 2017. Sarcopenia is getting prevalent over the
age gathering of 50-80 years. Severe sarcopenia is increasingly prevalent crosswise over individuals
of age bunch over 80 years. Severe sarcopenia influences both physical execution and quality which
incorporates loss of muscle mass.
Geographic analysis of Sarcopenia Treatment Market, North America is the significant region across
the world in terms of market share owing to surging prevalence of cancer and chronic diseases. Asia-
Pacific is also anticipated to exhibit highest growth rate over the forecast period 2018-2025 due to
escalating prevalence of geriatric population and surging incidences of diabetes.
Business News:
1 Sanofi SA (April 26, 2019) – ZynquistaTM now approved in the European Union for treatment of
adults with type 1 diabetes – The European Commission has granted marketing authorization for
Zynquista (sotagliflozin)*, developed by Sanofi and Lexicon. Zynquista is now approved in the
European Union, at once-daily doses of 200 mg and 400 mg, for use as an adjunct to insulin therapy
to improve blood sugar (glycemic) control in adults with type 1 diabetes (T1D) mellitus and a body
mass index ≥ 27 kg/m2, who could not achieve adequate glycemic control despite optimalinsulin
therapy.
“Millions of people across Europe who live with type 1 diabetes struggle tocontrol their blood sugar,
even with optimal insulin therapy,” commentedThomas Danne, Professor of Pediatrics, Children’s
Hospital ‘Auf der Bult,’Hannover, Germany. “For the many people living with type 1 diabetes who
are overweight or obese, Zynquista will offer a new treatment option physicians can now consider in
combination with insulin therapy for appropriate patients.”
Top Leading Key Manufacturers are: Abbott Laboratories, Pfizer Inc, Novartis AG, Glaxosmithkline
Plc, Nestle SA, Bayer AG, Sanofi SA, Amway and others. New product launches and continuous
technological innovations are the key strategies adopted by the major players.
With the presence of a large pool of participants, the Global Sarcopenia Treatment Market is
displaying a highly competitive business landscape, finds a new research report by Business Industry
Reports (BIR). Abbott Laboratories, Pfizer Inc, Novartis AG, Glaxosmithkline Plc, Nestle SA, Bayer AG,
Sanofi SA, Amway, etc. are some of the key vendors of Sarcopenia Treatment across the world.
These players across Sarcopenia Treatment Market are focusing aggressively on innovation, as well
as on including advanced technologies in their existing products.
Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents
on “Global Sarcopenia Treatment Market Report 2019” @
https://www.businessindustryreports.com/buy-now/157803/single .